Search results
Results from the WOW.Com Content Network
Maddrey's discriminant function (DF) is the traditional model for evaluating the severity and prognosis in alcoholic hepatitis and evaluates the efficacy of using alcoholic hepatitis steroid treatment. The Maddrey DF score is a predictive statistical model compares the subject's DF score with mortality prognosis within 30-day or 90-day scores.
10-20% of patients with alcoholic hepatitis progress to alcoholic liver cirrhosis every year. [10] Patients with liver cirrhosis develop liver cancer at a rate of 1.5% per year. [11] In total, 70% of those with alcoholic hepatitis will go on to develop alcoholic liver cirrhosis in their lifetimes. [10]
The Lille Model is a medical modeling tool for predicting mortality in patients with alcoholic hepatitis who are not responding to steroid therapy. The model risk stratifies patients who have been receiving steroid treatment for seven days to predict who will improve and who should be considered for alternative treatment options including early referral for transplant.
Hy's law is a rule of thumb that a patient is at high risk of a fatal drug-induced liver injury if given a medication that causes hepatocellular injury (not Hepatobiliary injury) with jaundice. [1] The law is based on observations by Hy Zimmerman, a major scholar of drug-induced liver injury.
A high gradient (> 1.1 g/dL, >11 g/L) indicates the ascites is due to portal hypertension, either liver related or non-liver related, with approximately 97% accuracy. [2] This is due to increased hydrostatic pressure within the blood vessels of the hepatic portal system , which in turn forces water into the peritoneal cavity but leaves proteins ...
The King's College criteria were described in a seminal publication in 1989 by J.G. O'Grady and colleagues from King's College School of Medicine. [2] 588 patients with acute liver failure who presented to King's College Hospital from 1973 to 1985 were assessed retrospectively to determine if there were particular clinical features or tests that correlated poorly with prognosis.
FibroTest has been evaluated in relation to liver biopsy (the current reference standard in liver disease assessment) in people with hepatitis C, hepatitis B, [1] alcoholic liver disease, [2] and non-alcoholic fatty liver disease. [3] They are most useful for cirrhosis and less useful for other stages of liver disease. [4]
Liver function tests (LFTs or LFs), also referred to as a hepatic panel or liver panel, are groups of blood tests that provide information about the state of a patient's liver. [1] These tests include prothrombin time (PT/INR), activated partial thromboplastin time (aPTT), albumin , bilirubin (direct and indirect), and others.